Allergan, Apricus Biosciences deal
Allergan granted Apricus exclusive rights to develop and commercialize Vitaros alprostadil in the U.S. Allergan will receive $1 million up front and is eligible to receive a $1.5 million regulatory milestone payment, plus double-digit royalties. Upon FDA acceptance of an NDA, Allergan may exercise an opt-in right to undertake sole commercialization in the U.S. If Allergan exercises the opt-in, Apricus will be eligible to receive up to $25 million in upfront and commercial milestone payments, plus double-digit royalties. Allergan retains rights to launch an authorized generic, with the partners sharing profits.
The topical prostaglandin E1 (PGE1) cream formulated with Apricus’ NexACT transdermal delivery technology is approved in Europe and Canada to treat erectile dysfunction (ED). ...